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background: Atrial fibrillation (AF) is common in patients with the HeartMate II (HMII) left ventricular assist device (LVAD). However, the clinical 
consequences of AF in this patient population are uncertain.
Methods: Records of 106 patients who underwent implantation of the HMII at a single center were reviewed. The association of AF with survival, 
heart failure (HF) hospitalization, bleeding and thromboembolism was examined using Kaplan-Meier survival analysis and Cox proportional hazards 
regression.
results: Mean age was 56.6±11.4 years, 82.1% were male, 42.5% had an ischemic cardiomyopathy, 87.7% were bridge to transplantation and 
median length of support was 217 days (range 1-952). Twenty-one (19.8%) patients died, and 18 (17.0%) were hospitalized for HF. There were 0.75 
major bleeding events and 0.28 thromboembolic events per patient year of follow-up. AF was present in 55 (51.9%) patients; 36 (34.0%) patients 
had paroxysmal AF and 19 (17.9%) had persistent AF. Patients with AF were more likely to be older, have chronic kidney disease and be diagnosed 
with HF for > 1 year. Persistent AF was an independent predictor of both increased mortality (HR, 3.22 [1.10-9.36], p=0.032) and increased 
hospitalizations for HF (HR, 3.98 [1.32 - 12.02], p=0.014). However, AF was not associated with an elevated risk of major bleeding (HR, 1.22 [0.59 - 
2.51], p=0.595) or thromboembolism (HR, 0.67 [0.25 - 1.80], p=0.423), though patients with AF had thromboembolic events at higher international 
normalized ratios (2.70 ± 0.94 vs. 1.54 ± 0.34, p=0.003).
conclusion: AF is present in half of patients with the HMII LVAD and is associated with worse outcomes despite the absence of an increased risk 
of bleeding and thromboembolism.
